Viewing nowSitaSingle Tablets 100 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 113.37mg
Tablet · Prescription medication
CMG Pharmaceutical Co., Ltd.

MFDS item code 202301821 · Approved 2023.06.14 · Insurance code 648604550
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy when starting treatment with diabetes medications. However, if blood sugar control is insufficient with monotherapy, it may be used in combination with metformin. Additionally, this medication can be used in conjunction with other diabetes treatments such as sulfonylureas, thiazolidinediones, or insulin if blood sugar control is challenging, even when used alone or together with these treatments. This medication effectively helps manage blood sugar levels in patients with type 2 diabetes.
This medicine is administered at 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, assessment of renal function before treatment with this medicine and periodically thereafter is recommended. 1. No dose adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2), administer 50 mg once daily. 4. In patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2), administer 25 mg once daily. This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions after administration. These reactions may include anaphylaxis, angioedema, and serious skin diseases. If such symptoms are suspected, immediately discontinue the medication and consult a physician. This medication can cause inflammation of the pancreas; therefore, if symptoms of pancreatitis such as abdominal pain, vomiting, or loss of appetite occur while on this medication, medical personnel should be informed immediately. Medication should be discontinued if necessary. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Additionally, patients with allergies to this medication or its components should avoid its use. Patients with impaired kidney function may have delayed excretion of this medication; hence, dosage adjustments should be made with caution. Especially patients with low glomerular filtration rates or those undergoing dialysis must strictly follow a physician's instructions. In clinical trials, this medication may cause hypoglycemic symptoms when used alone or in combination with other diabetes medications. The risk of hypoglycemia increases when taken with insulin or sulfonylureas, so blood sugar levels should be closely monitored. While taking this medication, symptoms such as headaches, upper respiratory infections, nasopharyngitis, diarrhea, and nausea may occur. If these symptoms persist or worsen, consult medical personnel. Serious side effects such as severe arthralgia or skin blistering conditions like bullous pemphigoid have been reported; if such symptoms occur, discontinue the medication immediately and consult a specialist. This medication is not recommended for pregnant women and should be avoided by breastfeeding women as well. Safety and efficacy in children under 18 have not been established. Elderly patients may have a risk of reduced kidney function; hence, dosage adjustments and regular monitoring of kidney function are necessary. In the case of overdose, the medication should be cleared from the gastrointestinal tract, and clinical conditions including cardiac function should be carefully monitored, and blood dialysis may be performed to remove some of the medication as needed.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture and should be kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy and prevent degradation.
Bright yellow-orange round film-coated tablets
Bottle pack - 30 tablets/bottle, Bottle pack - 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.37mg
Tablet · Prescription medication
CMG Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.